Lights and shadows on JAK inhibitors for Ankylosing Spondylitis

Eur J Intern Med. 2022 Aug:102:43-44. doi: 10.1016/j.ejim.2022.05.018. Epub 2022 May 21.

Authors

Giovanni Benanti¹, Lorenzo Dagna¹, Corrado Campochiaro²

Affiliations

¹ Unit of Immunology Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy.
² Unit of Immunology Rheumatology, Allergy and Rare Diseases. IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. Electronic address: campochiaro.corrado@hsr.it.

PMID: 35606287
DOI: 10.1016/j.ejim.2022.05.018

No abstract available

MeSH terms

Antirheumatic Agents* / therapeutic use
Humans
Janus Kinase Inhibitors* / therapeutic use
Spondylitis, Ankylosing* / drug therapy
Tumor Necrosis Factor-alpha

Substances

Antirheumatic Agents
Janus Kinase Inhibitors
Tumor Necrosis Factor-alpha